E-cadherin loss or decrease at the cell membrane of cancer cells has often been associated with worsening histological grade and clinical stage, along with poor prognosis in a variety of tumors, including breast, pancreatic, gastric, and prostate cancer [5,11,12,13,14]. Here, CDH1 is linked to prostate cancer.